XBP1 and cancer: Furthermore, some cetumximab-treated cancer cells that are resistant to immunogenic cell death, display increased XBP1s expression, and inhibition of XBP1 splicing restored tumor immunogenicity (Huo et al. 2020; Pozzi et al. 2016).